• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗一位 60 岁肾移植受者的复发性尿路感染。噬菌体治疗的应用。

Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy.

机构信息

Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.

Phage Therapy Unit, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.

出版信息

Transpl Infect Dis. 2021 Feb;23(1):e13391. doi: 10.1111/tid.13391. Epub 2020 Jul 14.

DOI:10.1111/tid.13391
PMID:32599666
Abstract

We would like to demonstrate the difficulty of treatment in a patient after kidney transplantation (KTX) who developed chronic urinary tract infection (UTI) with a multi-drug resistant ESBL-producing Klebsiella pneumoniae. The patient underwent several treatment interventions including supportive therapy with bacteriophages. This article presents a case of a 60-year-old patient after KTX repeatedly admitted to the hospital with recurrent UTIs caused by ESBL-producing Klebsiella pneumoniae showing variable susceptibility to carbapenems and full susceptibility to colistin only. KTX was performed due to renal insufficiency caused by polycystic kidney disease. The patient experienced 12 severe episodes of UTI due to K pneumoniae within 15 months since transplantation. In an attempt to curb the ongoing infections, phage therapy (PT) was applied on the experimental basis, coordinated by the Phage Therapy Unit of the Hirszfeld Institute in Wroclaw, Poland. Eventually, the patient fully recovered following nephrectomy of his own left kidney where cysts were the suspected reservoir of bacteria. The patient completed 29 days of PT. PT caused no reported side effects in the described case of the KTX recipient, although its role in controlling chronic UTI caused by K pneumoniae is unclear. More studies are needed in the population of kidney transplant recipients.

摘要

我们希望展示一位肾移植 (KTX) 后患者在治疗上的困难,该患者发生了多重耐药产 ESBL 肺炎克雷伯菌引起的慢性尿路感染 (UTI)。该患者接受了包括噬菌体支持治疗在内的几种治疗干预措施。本文介绍了一例 60 岁 KTX 后患者的病例,该患者因多囊肾病导致肾功能不全而接受 KTX,在移植后 15 个月内因产 ESBL 肺炎克雷伯菌引起的复发性 UTI 反复住院,其对碳青霉烯类药物的敏感性不同,对黏菌素完全敏感。该患者在移植后 15 个月内经历了 12 次严重的 K 肺炎引起的 UTI 发作。为了控制持续的感染,在波兰弗罗茨瓦夫 Hirszfeld 研究所噬菌体治疗单位的协调下,尝试进行了噬菌体治疗 (PT)。最终,在对其自身左肾进行了肾切除术(怀疑左肾囊肿是细菌的储存库)后,患者完全康复。该患者接受了 29 天的 PT。在描述的 KTX 受者病例中,PT 未引起任何已知的副作用,尽管其在控制由 K 肺炎引起的慢性 UTI 中的作用尚不清楚。在肾移植受者人群中还需要更多的研究。

相似文献

1
Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy.治疗一位 60 岁肾移植受者的复发性尿路感染。噬菌体治疗的应用。
Transpl Infect Dis. 2021 Feb;23(1):e13391. doi: 10.1111/tid.13391. Epub 2020 Jul 14.
2
Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.肾移植患者中由产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌引起的尿路感染:危险因素与分子流行病学
PLoS One. 2015 Aug 3;10(8):e0134737. doi: 10.1371/journal.pone.0134737. eCollection 2015.
3
A Dutch Case Report of Successful Treatment of Chronic Relapsing Urinary Tract Infection with Bacteriophages in a Renal Transplant Patient.荷兰病例报告:噬菌体成功治疗肾移植患者慢性复发性尿路感染
Antimicrob Agents Chemother. 2019 Dec 20;64(1). doi: 10.1128/AAC.01281-19.
4
Urinary Tract Infections Caused by in Kidney Transplant Recipients - Epidemiology, Virulence and Antibiotic Resistance.肾移植受者感染的尿路感染-流行病学、毒力和抗生素耐药性。
Front Cell Infect Microbiol. 2022 Apr 21;12:861374. doi: 10.3389/fcimb.2022.861374. eCollection 2022.
5
Clinical Significance of Gastrointestinal Carriage of Klebsiella Pneumoniae-Producing Extended-Spectrum Beta-Lactamases in Kidney Graft Recipients.产超广谱β-内酰胺酶肺炎克雷伯菌在肾移植受者胃肠道定植的临床意义
Transplant Proc. 2018 Jul-Aug;50(6):1874-1877. doi: 10.1016/j.transproceed.2018.03.114. Epub 2018 Mar 28.
6
Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation.实体器官移植后耐碳青霉烯类肺炎克雷伯菌尿路感染
Antimicrob Agents Chemother. 2015 Jan;59(1):553-7. doi: 10.1128/AAC.04284-14. Epub 2014 Nov 10.
7
Successful Treatment of Urinary Tract Infection in Kidney Transplant Recipients Caused by Multiresistant Klebsiella pneumoniae Producing New Delhi Metallo-Beta-Lactamase (NDM-1) With Strains Genotyping.肾移植受者中由产新德里金属β-内酰胺酶(NDM-1)的多重耐药肺炎克雷伯菌引起的尿路感染的成功治疗及菌株基因分型
Transplant Proc. 2016 Jun;48(5):1576-9. doi: 10.1016/j.transproceed.2016.01.060.
8
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections Due to Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae.克服抗生素耐药性:产超广谱β-内酰胺酶(ESBL)肺炎克雷伯菌引起的尿路感染使用高剂量阿莫西林克拉维酸。
Ann Transplant. 2023 May 16;28:e939258. doi: 10.12659/AOT.939258.
9
Extended-spectrum beta-lactamase and urinary tract infections.超广谱β-内酰胺酶与尿路感染。
Epidemiol Infect. 2020 Dec 17;149:e12. doi: 10.1017/S0950268820003015.
10
Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.氨基糖苷类药物治疗由产超广谱β-内酰胺酶的大肠埃希菌或肺炎克雷伯菌引起的儿童尿路感染。
BMC Infect Dis. 2015 Oct 13;15:414. doi: 10.1186/s12879-015-1153-z.

引用本文的文献

1
Dual Nature of Bacteriophages: Friends or Foes in Minimally Processed Food Products-A Comprehensive Review.噬菌体的双重性质:即最低限度加工食品中的朋友还是敌人——一篇综述
Viruses. 2025 May 29;17(6):778. doi: 10.3390/v17060778.
2
[Potential of bacteriophage therapy in Germany: evidence and clinical relevance].[德国噬菌体疗法的潜力:证据与临床相关性]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 Apr 28. doi: 10.1007/s00103-025-04048-y.
3
Phage therapy for Klebsiella pneumoniae: Understanding bacteria-phage interactions for therapeutic innovations.
肺炎克雷伯菌的噬菌体疗法:理解细菌与噬菌体的相互作用以实现治疗创新。
PLoS Pathog. 2025 Apr 8;21(4):e1012971. doi: 10.1371/journal.ppat.1012971. eCollection 2025 Apr.
4
Potential of a phage cocktail in the treatment of multidrug-resistant Klebsiella pneumoniae pulmonary infection in mice.噬菌体鸡尾酒疗法治疗小鼠耐多药肺炎克雷伯菌肺部感染的潜力
BMC Microbiol. 2025 Mar 17;25(1):151. doi: 10.1186/s12866-025-03851-6.
5
Emerging antimicrobial therapies for Gram-negative infections in human clinical use.目前正在临床应用的针对革兰氏阴性菌感染的新型抗菌疗法。
NPJ Antimicrob Resist. 2025 Feb 27;3(1):16. doi: 10.1038/s44259-025-00087-2.
6
Phages as potential life-saving therapeutic option in the treatment of multidrug-resistant urinary tract infections.噬菌体作为治疗多重耐药性尿路感染的潜在救命治疗选择。
Acta Biochim Pol. 2025 Feb 11;72:14264. doi: 10.3389/abp.2025.14264. eCollection 2025.
7
Phage therapy for extensively drug resistant infection: case report and evaluation of the distribution of phage and the impact on gut microbiome.噬菌体疗法治疗广泛耐药感染:病例报告及噬菌体分布评估和对肠道微生物群的影响
Front Med (Lausanne). 2024 Dec 20;11:1432703. doi: 10.3389/fmed.2024.1432703. eCollection 2024.
8
Phage Therapy: A Promising Treatment Strategy against Infections Caused by Multidrug-resistant .噬菌体疗法:一种针对多重耐药菌感染的有前景的治疗策略
Curr Pharm Des. 2025;31(13):1007-1019. doi: 10.2174/0113816128343976241117183624.
9
The rise, fall, and resurgence of phage therapy for urinary tract infection.用于治疗尿路感染的噬菌体疗法的兴衰与复兴
EcoSal Plus. 2024 Dec 12;12(1):eesp00292023. doi: 10.1128/ecosalplus.esp-0029-2023. Epub 2024 Jan 11.
10
Beyond Antibiotics: What the Future Holds.超越抗生素:未来会怎样。
Antibiotics (Basel). 2024 Sep 25;13(10):919. doi: 10.3390/antibiotics13100919.